Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Suspended 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Specimen Handling 6Gemcitabine 6Oxaliplatin 5Irinotecan 5S 1 (combination) 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4Capecitabine 4Biopsy 4Bevacizumab 4Radiotherapy 3Nivolumab 3Immunotherapy 3Drug Therapy 3trifluridine tipiracil drug combination 2titanium silicide 2spartalizumab 2lenvatinib 2aldesleukin 2Surgical Procedures, Operative 2Radiosurgery 2Photochemotherapy 2Interleukin-2 2Endoscopic Mucosal Resection 2Cyclophosphamide 2Cetuximab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × sotigalimab × Gastrointestinal × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡